window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

ASCO 2025

  • Clinical Development,Oncology,Partnerships & Funding,Precision medicine,Research & Development,RNA Therapeutics,Technology and platforms

    Strand lands $153M to advance programmable mRNA cancer therapies

    Boston-based Strand Therapeutics has raised $153 million in a Series [...]

    August 8, 2025
  • Artificial Intelligence,Market Access & Commercialization,Oncology

    Caris CMO on AI, equity, and the future of multi-omic oncology

    The former ASCO president shares his insights on breast cancer [...]

    July 4, 2025
  • Clinical Trials,Drug Delivery & Formulation,Oncology,Patient Centricity,Precision medicine,Technology and platforms

    Can cryoablation plus intratumora immunotherapy rewrite the rules of cancer treatment?

    Q&A with Dr Jason Williams, founder of the Williams Cancer [...]

    June 26, 2025
  • Artificial Intelligence,Clinical Trials

    Harbinger Health presents early cancer detection data for high-risk populations at ASCO 2025

    Harbinger Health has presented clinical data showing how its blood-based [...]

    June 9, 2025
  • Clinical Trials,Drug Development,Regulatory Affairs

    Why patient-centric trial design is the future of oncology: Q&A with One2Treat’s chief medical officer Pascal Piedbois

    As oncology research continues to evolve, the focus is increasingly [...]

    May 30, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top